Skip to content

Protein Supplementation to Enhance Exercise Capacity in COPD

A Double-Blind, Randomised, Placebo-Controlled Trial of Protein Supplementation to Enhance Exercise Capacity in Chronic Obstructive Pulmonary Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04027413
Enrollment
68
Registered
2019-07-22
Start date
2019-01-07
Completion date
2020-10-02
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Pulmonary Rehabilitation, Nutrtional supplements

Brief summary

Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung disease. Pulmonary Rehabilitation (PR) is a six-week supervised group exercise and education class. PR is an effective intervention in COPD to reduce symptoms, improve exercise performance and prevent exacerbation. Exercise intolerance/limitation is one of the commonest issues with COPD patients and this may be compounded by reduced muscle mass and malnutrition. COPD patients lose body weight and skeletal muscle mass which leads to muscle weakness and dysfunction, thus impacting functional ability and quality of life. Muscle weakness is caused by a prolonged sedentary lifestyle and voluntary immobilization. Importantly, being under-weight is associated with an increased risk of mortality in COPD. Nutritional supplementation have been used to overcome malnutrition in COPD patients. It has been shown that nutritional support integrated with exercise training can improve exercise activity, decreased the risk of mortality, and improve muscle strength in undernourished COPD patients. However, uptake of nutritional supplementation during pulmonary rehabilitation, where the potential benefit may be greatest, has been limited by the absence of rigorous evidence-based studies supporting use. Investigators want to investigate the effect of a nutritional supplement during a PR program on exercise capacity in COPD patients. Investigators will collect demographic data, distribute questionnaires, measure exercise performance, and some additional measurements.

Interventions

DIETARY_SUPPLEMENTfortisip compact protein

(24% protein; 41% carbohydrate; 35% fat)

DIETARY_SUPPLEMENTpreOp

(100% carbohydrate).

Sponsors

Nutricia, Inc.
CollaboratorINDUSTRY
University College, London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Participant in both groups will received either the supplement or the placebo/ control products. Both products will be labelled the same way. Investigator: someone not from the research team will run the randomisation and deliver the products to participants. Outcome Assessor: will not be involved in the randomisation and will be blinded

Intervention model description

Participants will be randomised using a web-based service called 'sealed envelope' and stratified BMI less and equal or more than 20 kg/m2 to control group or interventional group.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Confirmed COPD (post-bronchodilator forced vital capacity in one second: forced vital capacity ratio \<0.7) 2. \>10 smoking pack year history. 3. Enrolling on a pulmonary rehabilitation programme. 4. Age of 18 and above.

Exclusion criteria

1. Patients with any physical or mental health disorders preventing compliance with trial protocol. 2. Unable to communicate in English 3. Malabsorption syndrome 4. Unable to perform the Incremental Shuttle Walk Test 5. Patients already using other types of oral dietary supplement, under the care of a dietitian. 6. Galactosaemia (contraindication) 7. Known cow's milk protein allergy or lactose intolerance 8. BMI \>30kg/m2 without recent weight loss of \>5%

Design outcomes

Primary

MeasureTime frameDescription
Exercise capacity12 weeksThe difference in change of exercise capacity before and and after pulmonary rehabilitation between intervention and control groups measured by Incremental Shuttle Walk Test.

Secondary

MeasureTime frameDescription
Rectus femoris muscle cross-sectional12 weeksThe difference in change of Rectus femoris muscle cross-sectional area before and and after pulmonary rehabilitation between intervention and control groups measured by portable ultrasound.
Body composition12 weeksThe difference in change of body composition fat mass (FM) before and and after pulmonary rehabilitation between intervention and control groups measured by a device called Bodystat.
Physical activity14 daysThe difference in change of physical activity before and and after pulmonary rehabilitation between intervention and control groups measured by step-counter (YAMAX SW200).
Health-related quality of life12 weeksThe difference in change of health-related quality before and after pulmonary rehabilitation between intervention and control groups measured by Hospital Anxiety and Depression Scale. consists of seven items for anxiety and seven items for depression, each item has a score from 0-3.This means that a person can score between 0 and 21 for either abnormal, respectively. 0-7 = Normal, 8-10 = Borderline abnormal and 11-21 = Abnormal
Body circumferences12 weeksThe difference in change of waist circumference before and and after pulmonary rehabilitation between intervention and control groups measured by a tape.
Peripheral muscle strength12 weeksThe difference in change of peripheral muscle strength Before and and after pulmonary rehabilitation between intervention and control groups measured by Hand Dynamometer.
Food intake12 weeksFood intake for 3 consecutive days before, during, and after PR by food diary
Lower limb function12 weeksThe difference in change of lower limb function before and after pulmonary rehabilitation between intervention and control groups measured Sit to Stand - Five Test.
Malnutrition risk12 weeksThe difference in change of Malnourished risk before and after pulmonary rehabilitation between intervention and control groups measured Malnutrition Universal Screening Tool .
Disability associated with breathlessness12 weeksThe difference in change of Disability associated with breathlessness before and after pulmonary rehabilitation between intervention and control groups measured by Medical Research Council breathlessness scale .
Body weight12 weeksThe difference in change of body weight before and after pulmonary rehabilitation between intervention and control groups measured by digital scales.
intervention compliance6 weeksparticipants intervention compliance will be assessed by sheet

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026